Loading
The IL-11 receptor was the target of oprelvekin, the first drug approved to prevent the severe platelet falls that chemotherapy causes; the drug was withdrawn in 2011 and thrombopoietin agonists took over the problem.
Interleukin-11 receptor subunit alpha pairs with gp130 to carry the signal of interleukin-11, a cytokine that drives megakaryocytes to mature and release platelets. Recombinant IL-11 (oprelvekin, Neumega) was approved in the United States in 1997 to prevent severe thrombocytopenia after myelosuppressive chemotherapy, but fluid retention and cardiac side effects limited its use and it was withdrawn from the market in 2011. IL-11 signalling is now studied as a driver of fibrosis and of tumour-supporting inflammation in stomach and bowel cancers.
In plain words · The IL-11 receptor was the target of oprelvekin, the first drug approved to prevent the severe platelet falls that chemotherapy causes; the drug was withdrawn in 2011 and thrombopoietin agonists took over the problem.
The IL-11 receptor was the target of oprelvekin, the first drug approved to prevent the severe platelet falls that chemotherapy causes; the drug was withdrawn in 2011 and thrombopoietin agonists took over the problem.
A cytokine receptor of the IL-6 family; ligand binding recruits gp130 and activates JAK-STAT3 signalling in megakaryocytes, epithelial cells and fibroblasts.
1 product aims at IL-11 receptor alpha: other agents. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Immune or microenvironment target: its medicines act on immune, stromal or bone cells rather than on the tumour cell (drug mechanisms in the corpus). HPA IL11RA: RNA tissue enhanced (heart muscle 36 nTPM); high antibody staining in 7 normal tissues; highest cancer staining liver cancer (4 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Gastric & gastro-oesophageal junction cancer, Colorectal cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 1 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas IL11RA tissue; UniProt Q14626; Open Targets ENSG00000137070 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Cherel et al, Blood, 1995, "Molecular cloning of two isoforms of a receptor for the human hematopoietic cytokine interleukin-11". Source.
A cytokine receptor of the IL-6 family; ligand binding recruits gp130 and activates JAK-STAT3 signalling in megakaryocytes, epithelial cells and fibroblasts.
RNA: tissue enhanced (heart muscle 36 nTPM), detected in many normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Bronchus, Caudate, Cerebellum, Cerebral cortex, Cervix.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
HPA IL11RA tissue · HPA IL11RA pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | host% | Host target: IL-11 receptor on platelet precursors. Not a tumour alteration, so no prevalence applies; the drug acts on normal tissue or on symptoms. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Oprelvekin was the first drug approved, in 1997, to prevent the severe platelet falls that chemotherapy causes, but fluid retention and heart rhythm problems limited it and it was withdrawn in 2011; thrombopoietin agonists took over the problem.
Query for this target: (TITLE:"IL-11 receptor alpha" OR ABSTRACT:"IL-11 receptor alpha" OR TITLE:"IL11RA" OR ABSTRACT:"IL11RA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IL-11 receptor alpha, not a curated reading list.
Shares Oprelvekin, Thrombocytopenia.
Shares Oprelvekin, Thrombocytopenia.
Shares Thrombocytopenia, Colorectal cancer.